Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

William Ellis

Technician/Technologist, Ophthalmic El Cerrito, CA Medical Doctor

NPI 1619029352 CMS profile 1304505

6500 Fairmount Ave, El Cerrito, CA 94530

Open in the dashboard

General payments

$3,856

123 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, William Ellis of El Cerrito, CA is reported in the CMS Open Payments database as having received $3,856 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $23 1
2022 General $267 11
2021 General $809 44
2020 General $638 41
2019 General $2,118 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Ellis
  • California median
  • Middle half of California
  • National median

In program year 2025, general payments to William Ellis were reported at $0. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.

Show as a table
Year William Ellis California median Middle half National median
2019 $2,118 $161 $50–$652 $163
2020 $638 $114 $34–$392 $114
2021 $809 $137 $41–$509 $132
2022 $267 $152 $48–$573 $149
2023 $23 $162 $50–$581 $160
2024 $0 $162 $52–$583 $164
2025 $0 $172 $54–$610 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Eyevance Pharmaceuticals LLC $1,816 29 payments
  2. Kala Pharmaceuticals, Inc. $994 59 payments
  3. Bausch & Lomb, a division of Bausch Health US, LLC $330 9 payments
  4. TissueTech, Inc. $329 12 payments
  5. Allergan Inc. $182 3 payments
  6. Bausch & Lomb Americas Inc. $143 7 payments
  7. Johnson & Johnson Surgical Vision, Inc. $39 3 payments
  8. Shire North American Group Inc $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,606 122 payments
  2. Consulting Fee $1,250 1 payment
Products named General payments · program years 2019–2023
  1. Flarex Ophthalmology $1,481 12 payments
  2. INVELTYS $994 59 payments
  3. EYSUVIS $422 25 payments
  4. LOTEMAX SM $317 13 payments
  5. VYZULTA $315 8 payments
  6. PROKERA $301 11 payments
  7. AMNIOGRAFT $301 11 payments
  8. Flarex Ophthalmic $205 10 payments
  9. OPHTHALMIC INSTRUMENTS $183 2 payments
  10. STELLARIS PC $183 2 payments
  11. Other $902 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record